Algenex Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Employees
  • 20
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $8.76M
Latest Deal Amount
  • Investors
  • 13

Algenex General Information

Description

Developer of novel subunit vaccines designed to manufacture recombinant proteins. The company's technology uses a baculovirus expression vector system for vaccine manufacturing, diagnostic reagents, crystallography, and therapeutic molecules, enabling healthcare providers to study and understand unprecedented performance and proteolysis reduction.

Contact Information

Website
www.algenex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Ronda de Poniente 14
  • Bajo ala izquierda, Tres Cantos
  • 28760 Madrid
  • Spain
+34 913 00 00 00

Algenex Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Algenex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 08-Sep-2020 $8.76M 000.00 Completed Generating Revenue
3. Later Stage VC 05-Mar-2019 00.000 000.00 Completed Generating Revenue
2. Grant $5.85M Completed Startup
1. Early Stage VC $5.85M $5.85M Completed Startup
To view Algenex’s complete valuation and funding history, request access »

Algenex Executive Team (12)

Name Title Board Seat Contact Info
Claudia Jimenez Chief Executive Officer and General Manager
Virginia Álvarez Chief Financial Officer
Virginia Gonzalez Chief Financial Officer
Romy Dalton Chief Operations Officer
Jose Escribano Ph.D Co-Founder, Chief Scientific Officer & Chairman
You’re viewing 5 of 12 executive team members. Get the full list »

Algenex Board Members (9)

Name Representing Role Since
Claudia D'Augusta Ph.D Self Board Member 000 0000
Daniel Toribio Self Board Member 000 0000
Jose Escribano Ph.D Algenex Co-Founder, Chief Scientific Officer & Chairman 000 0000
Lorenzo Salieri Algenex Board Member 000 0000
Martin Rivas Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Algenex Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Algenex Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Columbus Venture Partners Venture Capital Minority 000 0000 000000 0
MasterLux Venture Capital Minority 000 0000 000000 0
Chamberi Ventures Venture Capital Majority 000 0000 000000 0
Cleone Capital Other Minority 000 0000 000000 0
Nomainvest PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »